Immunometabolism therapies could offer a way to reverse inflammation and cure diseases, according to Neil Weir, CEO of Sitryx. This emerging field in therapeutics looks at the overlap between metabolic pathways and the immune cell synthesis process, allowing very specific targeted therapies which influence the immune system without causing dangerous side effects. Sitryx has three drugs in various stages of development for a variety of autoimmune diseases, while Texas-based ImmunoMet is likewise developing lixumistat, which has various uses including in pancreatic cancer trials.
Tariff support for health IT launched in South Korea following Trump’s tariff and more briefs
The South Korean government has launched a tariff support center to assist medical device companies with trade challenges, particularly related to U.S. tariffs. Meanwhile, Johnson
